NCT01791478View on ClinicalTrials.gov

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2025

Conditions
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast CarcinomaProgesterone Receptor-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

PI3K inhibitor BYL719

Given PO

DRUG

letrozole

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological studies

Correlative studies

Trial Locations (2)

02114

Massachusetts General Hospital, Dana-Farber Cancer Institute, Boston

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER